Companies › Eloxx Pharmaceuticals
1 active drug program in 1 registered trial: 1 Phase 2; Other; next expected readout Jun 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Elx-02 80S Ribosome modulator | RPSA, RPS27, RPS6, RPS2, RPS3 | Phase 2 | Alport Syndrome, X-Linked | Jun 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07523581 | Elx-02 | Phase 2 | Alport Syndrome, X-Linked | Other | Jun 2027 |
Cash of $62m on 2026-06-30; operating cash outflow about $21m a year; runway about 36 months at that burn, to Jun 2029; 1 of 1 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
Held by 3 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
QED Therapeutics, a BridgeBio company Healx Skingenix Sensory Cloud Shanghai Huilun Pharmaceutical
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.